New drug CDX-622 tested for safety in healthy people
NCT ID NCT06650761
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 trial tested the safety of a new drug called CDX-622 in 85 healthy adults aged 18-55. Participants received either CDX-622 or a placebo (saline) by infusion or injection. The study measured side effects, drug levels in the blood, and immune responses. Since it involved healthy volunteers, there was no treatment benefit; the goal was to gather safety data for future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CDX-622
- What could go wrong
- This is an early safety study in healthy people, so it won't show if CDX-622 works for any disease. Side effects are possible, and the drug may not be effective in future trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Celerion, Inc.
Tempe, Arizona, 85283, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates